Deals
The deal, which sees AbbVie paying RemeGen $650 million upfront, gives the pharma ex-China rights to the biotech’s PD-1/VEGF bispecific antibody—a modality being targeted by companies including BMS, Merck and Pfizer.
FEATURED STORIES
After a strong open to the year, the public markets suffered a six-month drought that led to biotech’s tightest IPO window in years.
While Novartis secured the biggest deal of the fourth quarter, a handful of riveting tales emerged from the bottom of the M&A list, including a zombie buyout and a bidding war. And no, we’re not talking about Metsera.
Four of this year’s biggest acquisitions topped 11-figure figures. One was 2025’s messiest bidding war.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Evotec SE announced that the Company successfully issued a Schuldschein of EUR 250 m on the capital market.
Global Blood Therapeutics, Inc. announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT.
NOXXON Pharma N.V. hereby announces the launch and terms of a share capital increase with shareholders’ preferential rights for an amount of up to € 3.9 million.
Humira generates about 60% of AbbVie’s annual revenue but is expected to lose patent protection in 2023.
Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.
The Management Board of MagForce AG has resolved and successfully completed, with the approval of the Supervisory Board, on basis of the authorization provided for in the Company’s articles of association, an increase of the registerd share capital of the Company from currently EUR 26,463,802.00 to EUR 27,640,274.00 by issuing 1,176,472 new no-par value bearer shares under exclusion of the shareholders’ statutory subscription rights.
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.
Mirati Therapeutics, Inc. announced that it has commenced an underwritten public offering of shares of its common stock.
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.
Medtronic plc announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc.